异丙酚激活蛋白激酶C对心肌缺血再灌注损伤的保护作用

目的:观察异丙酚对大鼠离体心肌缺血再灌注的影响及蛋白激酶C激活的作用。方法:实验于2004-04/2005-03在河北省医学科学院药研室完成。48只大鼠离体心脏随机分为6组,每组8只。分别为:正常对照组,持续灌注Lock液65min;缺血再灌注模型组,用含脂肪乳对照的灌流液灌注15min后,以钳夹主动脉灌注管造成全心常温缺血25min后,恢复再灌注30min,灌流液与预灌时相同;异丙酚15,30,60μmol/L组,缺血前和再灌期的灌流液中分别含相应浓度的异丙酚,余同缺血再灌注模型组;异丙酚60μmol/L 蛋白激酶抑制剂5μmol/L组,灌流液中含5μmol/L的chelerythrine的灌流液,其余同异丙酚60μmol/L组。实验评估:①Powerlab/8s仪记录各组平衡末、缺血前及再灌30min时心率、左室发展压、左室舒张末压、左室压力变化速率、冠状动脉流量等心功能指标。②测定冠状动脉流出液中乳酸脱氢酶、磷酸肌酸激酶活性。③透射电镜观察心肌细胞超微结构变化。④差速离心提取心肌线粒体,测定线粒体超氧化物岐化酶、谷胱甘肽过氧化物酶、ATP酶活性和丙二醛含量。结果:48只大鼠均进入结果分析。①平衡灌注末、缺血前各组间心功能指标差异无显著性(P>0.05),再灌注30min末,异丙酚30,60μmol/L组左室发展压、左室压力变化速率、冠状动脉流量明显高于缺血再灌注模型组(P<0.05),左室舒张末压明显低于缺血再灌注模型组(P<0.05)。异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组左室发展压、左室压力变化速率、冠状动脉流量明显低于单纯异丙酚60μmol/L组(P<0.05),但仍高于与缺血再灌注模型组(P<0.05)。②心肌缺血再灌后,冠状动脉流出液中乳酸脱氢酶和肌酸激酶活性明显高于正常对照组(P<0.05)。异丙酚30,60μmol/L组、异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组乳酸脱氢酶、肌酸激酶活性明显低于缺血再灌注模型组(P<0.05),异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组乳酸脱氢酶和肌酸激酶活性与异丙酚60μmol/L组无明显差异。③与缺血再灌注模型组相比,异丙酚组心肌损伤明显减轻,尤其是60μmol/L组,心肌纤维排列均匀,线粒体膜结构完整,仅轻度水肿,嵴清晰,糖原可见。异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组心肌超微结构显示损伤程度重于异丙酚60μmol/L组。④异丙酚30,60μmol/L、异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组丙二醛含量低于缺血再灌注模型组(P<0.05),ATP酶、超氧化物歧化酶、谷胱甘肽过氧化物酶活性明显高于缺血再灌注模型组(P<0.05)。异丙酚60μmol/L组与异丙酚60μmol/L 蛋白激酶C抑制剂5μmol/L组相比,上述指标无明显差异。结论:异丙酚对离体大鼠心肌缺血再灌注损伤有保护作用,可能与其抗脂质过氧化和激活蛋白激酶C有关。     

MicroRNAs in gene regulation: when the smallest governs it all

Encoded by the genome of most eukaryotes examined so far, microRNAs (miRNAs) are small approximately 21-nucleotide (nt) noncoding RNAs (ncRNAs) derived from a biosynthetic cascade involving sequential processing steps executed by the ribonucleases (RNases) III Drosha and Dicer. Following their recent identification, miRNAs have rapidly taken the center stage as key regulators of gene expression. In this review, we will summarize our current knowledge of the miRNA biosynthetic pathway and its protein components, as well as the processes it regulates via miRNAs, which are known to exert a variety of biological functions in eukaryotes. Although the relative importance of miRNAs remains to be fully appreciated, deregulated protein expression resulting from either dysfunctional miRNA biogenesis or abnormal miRNA-based gene regulation may represent a key etiologic factor in several, as yet unidentified, diseases. Hence is our need to better understand the complexity of the basic mechanisms underlying miRNA biogenesis and function.     

大豆甙元—PVP共沉淀物的制备及其体外溶出度的研究

以乙醇为溶媒用溶剂蒸发法制备了大豆甙元—PVP共沉淀物。X-衍射分析和偏光显微镜观察的结果表明,形成共沉淀物所需的PVP比例应大于5:1。体外溶出度试验结果表明,共沉淀物可以显著提高大豆甙元的体外溶出度。大豆甙元:PVP(1:10)的共沉淀物制成片剂后,在1 h内,90%以上的大豆甙元释放于蒸馏水或人工肠液中。     

A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis

We have recently completed a double-blind, placebo-controlled, noncrossover study, the goal of which was to determine whether cetiedil citrate (cetiedil) could affect the course of vaso-occlusive crises in sickle cell disease. Patients, who presented to the emergency room at least 4 but no more than 24 hours after the onset of a painful vasoocclusive crisis severe enough to require hospitalization, were considered candidates for the study. Each patient received either placebo or cetiedil at one of the following three dosages: 0.2, 0.3, or 0.4 mg/kg body weight. The assigned drug dosage was given as a 30 minute intravenous infusion every 8 hours for 4 consecutive days. A total of 67 patients was enrolled in the study. Cetiedil, at its highest dosage (0.4 mg/kg body weight), was found to be significantly superior to placebo both in reducing the number of painful sites present on all 4 treatment days and in shortening the total time in crisis. No serious adverse reactions were observed during the course of the study. We conclude that cetiedil, given at a dosage of 0.4 mg/kg body weight, is therapeutically advantageous for sickle cell crisis.